Biofrontera Inc (NASDAQ: BFRI) recently announced that the database lock for its Phase I pharmacokinetic study of Ameluz® for actinic keratosis on the trunk and extremities has been completed.

老虎证券2026/02/17 14:20

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This critical step marks the official completion of the clinical trial data collection phase, laying a solid foundation for subsequent data analysis and results evaluation. The company stated that the advancement of this study will further enrich the clinical application data of Ameluz® in the field of dermatological disease treatment.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Biofrontera Inc (NASDAQ: BFRI) recently announced that the database lock for its Phase I pharmacokinetic study of Ameluz® for actinic keratosis on the trunk and extremities has been completed.

You may also like

Crypto prices